CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1346-1358

  Jablonska, J ^a   Wu, C F ^a   Andzinski, L ^a   Leschner, S ^a   Weiss, S ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

chemokines; IFN ; migration; neutrophils; tumor

Indexed keywords

BETA INTERFERON; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CARCINOGENESIS; FEMALE; IMMUNOREGULATION; LEUKOCYTE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ASSOCIATED NEUTROPHIL; WILD TYPE;

EID: 84891836500     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28551     Document Type: Article

References (45)

1. Conti I, Rollins BJ,. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004; 14: 149-54.
2. Folkman J,. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
3. Semenza GL,. A new weapon for attacking tumor blood vessels. N Engl J Med 2008; 358: 2066-7.
4. Ferrara N, Kerbel RS,. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
5. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131: 463-75.
6. Singh S, Varney M, Singh RK,. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 2009; 69: 411-15.
7. Distler JH, Hirth A, Kurowska-Stolarska M, et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003; 47: 149-61.
8. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1-8.
9. Dhawan P, Richmond A,. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002; 72: 9-18.
10. Strieter RM, Burdick MD, Gomperts BN, et al. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609.
11. Cacalano G, Lee J, Kikly K, et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994; 265: 682-4.
12. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587-96.
13. Eash KJ, Greenbaum AM, Gopalan PK, et al. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest 2010; 120: 2423-31.
14. Mei J, Liu Y, Dai N, et al. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 2010; 33: 106-17.
15. Pruenster M, Mudde L, Bombosi P, et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 2009; 10: 101-8.
16. Jablonska J, Leschner S, Westphal K, et al. Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010; 120: 1151-64.
17. Tazzyman S, Lewis CE, Murdoch C,. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90: 222-31.
18. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-31.
19. de Visser KE, Eichten A, Coussens LM,. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
20. Nozawa H, Chiu C, Hanahan D,. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006; 103: 12493-8.
21. Owens GK, Kumar MS, Wamhoff BR,. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
22. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-65.
23. Peng W, Ye Y, Rabinovich BA, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010; 16: 5458-68.
24. Jablonska J, Leschner S, Westphal K, et al. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010; 120: 1151-64.
25. Semenza GL,. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003; 54: 17-28.
26. Nathan C,. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173-82.
27. Kim MH, Liu W, Borjesson DL, et al. Dynamics of neutrophil infiltration during cutaneous wound healing and infection using fluorescence imaging. J Invest Dermatol 2008; 128: 1812-20.
28. Gillitzer R, Goebeler M,. Chemokines in cutaneous wound healing. J Leukoc Biol 2001; 69: 513-21.
29. Soehnlein O, Lindbom L,. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 2010; 10: 427-39.
30. Pelletier M, Maggi L, Micheletti A, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010; 115: 335-43.
31. Scapini P, Laudanna C, Pinardi C, et al. Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur J Immunol 2001; 31: 1981-8.
32. Buonocore S, Surquin M, Le MA, et al. Amplification of T-cell responses by neutrophils: relevance to allograft immunity. Immunol Lett 2004; 94: 163-6.
33. Gregory AD, Houghton AM,. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71: 2411-16.
34. Fridlender ZG, Albelda SM,. Tumor-associated neutrophils: friend or foe? Carcinogenesis 2012; 33: 949-55.
35. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: «N1» versus «N2» TAN. Cancer Cell 2009; 16: 183-94.
36. Haghnegahdar H, Du J, Wang D, et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol 2000; 67: 53-62.
37. Rubie C, Frick VO, Wagner M, et al. ELR+ CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer 2008; 8: 178.
38. Kakinuma T, Hwang ST,. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006; 79: 639-51.
39. Zlotnik A,. Chemokines and cancer. Int J Cancer 2006; 119: 2026-9.
40. Zlotnik A, Burkhardt AM, Homey B,. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011; 11: 597-606.
41. Lazennec G, Richmond A,. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010; 16: 133-44.
42. Keeley EC, Mehrad B, Strieter RM,. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008; 28: 1928-36.
43. Dunn GP, Koebel CM, Schreiber RD,. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-48.
44. Smyth MJ,. Type I interferon and cancer immunoediting. Nat Immunol 2005; 6: 646-8.
45. Diamond M.S. Kinder M. Matsushita H. et al. Type i interferon is selectively required by dendritic cells for immune rejection of tumors J Exp Med 2011 208 1989-2003.